This is a transformative catalyst for BBIO. The PROPEL 3 data are best-in-class across all key endpoints with a clean safety profile, and the NEJM publication adds credibility. NDA submission in Q3 2026 and potential approval/launch in early to mid 2027 provide a clear regulatory catalyst timeline. Monitor for any FDA filing acceptance or priority review designation. The stock may gap up significantly on this data release.
Price Chart
Executive Summary
BridgeBio announced positive Phase 3 PROPEL 3 results for oral infigratinib in achondroplasia, published in NEJM and presented at ICCBH. The drug met primary and key secondary endpoints with the largest annualized height velocity improvement in any Phase 3 achondroplasia study and first statistically significant body proportionality improvement. NDA submission to FDA is planned for Q3 2026 with US launch anticipated in early to mid 2027.
Key Facts
- Phase 3 PROPEL 3 met primary endpoint: LS mean treatment difference in annualized height velocity +1.74 cm/yr (p<0.0001); observed mean difference +2.10 cm/yr
- Key secondary endpoint met: height Z-score LS mean increase +0.41 SD (p<0.0001)
- First statistically significant body proportionality improvement in achondroplasia: LS mean treatment difference -0.05 (p<0.05) in children <8 years
- New arm span Z-score data: LS mean +0.37 SD vs placebo (p<0.0001), first statistically significant result in a placebo-controlled achondroplasia trial
- No discontinuations or serious adverse events related to study drug; 3 mild transient hyperphosphatemia cases (4%)
- Breakthrough Therapy, Orphan Drug, Fast Track, and Rare Pediatric Disease Designations from FDA; potential Priority Review Voucher if approved
- NDA submission planned Q3 2026; US launch anticipated early to mid 2027; MAA to EMA in H2 2026
Financial Impact
Achondroplasia affects ~55,000 people in US and EU, including up to 10,000 children with open growth plates. First-in-class oral therapy with best-in-class efficacy data positions infigratinib for significant commercial opportunity. No revenue or deal values disclosed.
Risk Factors
- Regulatory risk: FDA may request additional data or have concerns about the NDA package despite Breakthrough Therapy designation
- Competition: existing injectable therapy (Vosoritide) and other oral candidates in development could limit market share
- Commercial execution risk: launch in early to mid 2027 requires successful manufacturing, pricing/reimbursement, and market access
- Dilution risk: potential need for additional capital to fund launch and pipeline, though market cap of $13.7B provides flexibility
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3318616 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | 8-K | $76.59 $65.97 | ▼ −13.87% | ▼ −13.68% | $67.47 (−11.90%) |
Aug 26, 2026 5w ago | Press Release | $79.37 $66.28 | ▼ −16.49% | ▼ −16.72% | $67.47 (−14.99%) |
Aug 22, 2026 5w ago | Institutional Cluster | $81.07 $69.23 | ▼ −14.60% | ▼ −15.92% | $67.47 (−16.77%) |
Aug 17, 2026 6w ago | 8-K | $79.89 $72.38 | ▼ −9.40% | ▼ −7.87% | $67.47 (−15.54%) |
Aug 13, 2026 7w ago | Press Release | $79.86 $72.38 | ▲ +9.37% | ▲ +7.38% | $67.47 (+15.51%) |
Aug 10, 2026 7w ago | 8-K | $84.67 $76.08 | ▼ −10.15% | ▼ −9.09% | $67.47 (−20.31%) |
Aug 10, 2026 7w ago | Press Release | $84.67 $76.08 | ▼ −10.15% | ▼ −9.09% | $67.47 (−20.31%) |
Jul 13, 2026 11w ago | Insider Cluster | $83.08 $84.67 | ▲ +1.91% | ▼ −1.27% | $67.47 (−18.78%) |
Jun 28, 2026 13w ago | Press Release | $72.01 $84.02 | ▲ +16.68% | ▲ +16.96% | $67.47 (−6.30%) |
Jun 24, 2026 14w ago | 144 | $69.69 $82.93 | ▲ +19.00% | ▲ +18.47% | $67.47 (−3.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access